GT200500242A - Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas - Google Patents

Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas

Info

Publication number
GT200500242A
GT200500242A GT200500242A GT200500242A GT200500242A GT 200500242 A GT200500242 A GT 200500242A GT 200500242 A GT200500242 A GT 200500242A GT 200500242 A GT200500242 A GT 200500242A GT 200500242 A GT200500242 A GT 200500242A
Authority
GT
Guatemala
Prior art keywords
processes
preparation
oxoisoindolines
dioxopiperidin
substituted
Prior art date
Application number
GT200500242A
Other languages
English (en)
Spanish (es)
Inventor
George W Muller
Roger Chen
Manohar Tukaram Saindane
Chuansheng Ge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35385616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200500242(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200500242A publication Critical patent/GT200500242A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GT200500242A 2004-09-03 2005-09-02 Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas GT200500242A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60740904P 2004-09-03 2004-09-03

Publications (1)

Publication Number Publication Date
GT200500242A true GT200500242A (es) 2006-06-22

Family

ID=35385616

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500242A GT200500242A (es) 2004-09-03 2005-09-02 Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas

Country Status (22)

Country Link
US (1) US7863451B2 (enExample)
EP (2) EP1797068B1 (enExample)
JP (2) JP2008512379A (enExample)
KR (1) KR20070057907A (enExample)
CN (1) CN101080400A (enExample)
AR (1) AR050724A1 (enExample)
AU (1) AU2005282728A1 (enExample)
BR (1) BRPI0514865A (enExample)
CA (1) CA2579291C (enExample)
ES (2) ES2437592T3 (enExample)
GT (1) GT200500242A (enExample)
HN (1) HN2005000508A (enExample)
IL (1) IL181674A0 (enExample)
MX (1) MX2007002521A (enExample)
NZ (1) NZ554068A (enExample)
PA (1) PA8643901A1 (enExample)
PE (1) PE20060648A1 (enExample)
SV (1) SV2007002219A (enExample)
TW (1) TW200621748A (enExample)
UY (1) UY29097A1 (enExample)
WO (1) WO2006028964A1 (enExample)
ZA (1) ZA200702382B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
DK2380887T3 (da) * 2005-06-30 2013-10-07 Celgene Corp Fremgangsmåder til fremstilling af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion-forbindelser
CN101186611B (zh) * 2006-11-15 2011-05-18 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用
WO2009114601A2 (en) * 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
DE102008057285A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung
DE102008057335A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Amorphes Lenalidomid
DE102008057284A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
WO2010056384A1 (en) * 2008-11-17 2010-05-20 Dr. Reddy's Laboratories Ltd. Lenalidomide solvates and processes
EP2396312A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
CN102414196A (zh) * 2009-03-02 2012-04-11 基因里克斯(英国)有限公司 改进的方法
CN101580501B (zh) 2009-06-01 2011-03-09 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
MX2012001890A (es) * 2009-08-12 2012-03-26 Synthon Bv Sales de lenalidomida.
US20120220777A1 (en) * 2009-09-16 2012-08-30 Ranbaxy Laboratories Limited Process for the preparation of a crystalline form of lenalidomide
TWI475014B (zh) 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
WO2011050962A1 (en) 2009-10-29 2011-05-05 Ratiopharm Gmbh Acid addition salts of lenalidomide
CN102127054B (zh) * 2009-11-02 2013-04-03 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN102060842B (zh) * 2009-11-02 2013-05-08 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
WO2011069608A1 (en) * 2009-12-09 2011-06-16 Ratiopharm Gmbh S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
CN101817813B (zh) * 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物
LT3202460T (lt) 2010-02-11 2019-10-10 Celgene Corporation Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
CN102453021A (zh) * 2010-10-22 2012-05-16 重庆医药工业研究院有限责任公司 来那度胺的新晶型及其制备方法
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
WO2013012485A2 (en) * 2011-07-19 2013-01-24 Amplio Pharma, Llc Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2877462B1 (en) * 2012-07-27 2019-09-04 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
HK1211577A1 (en) 2012-08-09 2016-05-27 细胞基因公司 Processes for the preparation of (s)-3-4- ((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
CN103242215A (zh) * 2013-05-27 2013-08-14 合肥医工医药有限公司 一种来那度胺中间体的制备方法
US10392364B2 (en) 2014-08-11 2019-08-27 Avra Laboratories Pvt. Ltd. Process for synthesis of lenalidomide
PL3214081T3 (pl) 2014-10-30 2021-04-06 Kangpu Biopharmaceuticals, Ltd. Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie
CN104447689B (zh) * 2014-12-22 2016-07-20 上海迈柏医药科技有限公司 来那度胺的晶型及其制备方法
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CN108191826A (zh) * 2018-01-08 2018-06-22 浙江省医学科学院 一种来那度胺晶体及其制备方法
MX2020011183A (es) 2018-04-23 2020-11-12 Celgene Corp Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
DK3820573T3 (da) 2018-07-10 2023-10-23 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
KR20210056397A (ko) * 2018-09-07 2021-05-18 메드샤인 디스커버리 아이엔씨. 삼환식 치환 피페리딘 디온계 화합물
CA3119343C (en) 2018-11-13 2024-01-16 Biotheryx, Inc. Substituted isoindolinones
CN109369504B (zh) * 2018-12-06 2020-05-12 温州大学 含硫3-亚甲基异吲哚啉-1-酮衍生物的制备方法
WO2025118133A1 (zh) * 2023-12-05 2025-06-12 浙江普洛家园药业有限公司 一种(s)-来那度胺-5-位衍生物及其合成方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
DE4236880A1 (de) * 1992-10-31 1994-05-05 Basf Ag N-Phenyl substituierte Glutarimide und N-Phenylglutarsäureamide, deren Herstellung und Verwendung
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
ATE530542T1 (de) * 1996-07-24 2011-11-15 Celgene Corp Amino substituierte 2-(2,6-dioxopiperidin-3-yl)- phthalimide zur verringerung der tnf-alpha-stufen
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
CA2262906C (en) * 1996-08-12 2006-10-31 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
BR9908811A (pt) * 1998-03-16 2000-12-05 Celgene Corp Composto, composição farmacêutica e seu uso no tratamento de mamìferos
ATE306469T1 (de) * 1999-03-18 2005-10-15 Celgene Corp Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine
EP1193248A1 (en) * 2000-09-30 2002-04-03 Aventis Pharma Deutschland GmbH Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7812169B2 (en) * 2000-11-30 2010-10-12 The Children's Medical Center Corporation Method of synthesis of 4-amino-thalidomide enantiomers
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
JP2002284761A (ja) * 2001-01-17 2002-10-03 Toray Ind Inc 光学活性３−アミノピロリジン−２，５−ジオン誘導体および光学活性３−アミノピロリジン誘導体の製造方法
ES2325916T3 (es) * 2001-08-06 2009-09-24 The Children's Medical Center Corporation Actividad antiangiogenica de analogos de talidomida sustituidos con nitrogeno.
US7091343B2 (en) * 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CH696542A5 (de) * 2003-07-09 2007-07-31 Siegfried Ltd Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen.
DK2380887T3 (da) * 2005-06-30 2013-10-07 Celgene Corp Fremgangsmåder til fremstilling af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion-forbindelser
EP1919892B1 (en) * 2005-08-31 2013-08-14 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
DK2076260T3 (da) * 2006-09-15 2011-06-27 Celgene Corp N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse
WO2009114601A2 (en) 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
WO2009111948A1 (zh) 2008-03-13 2009-09-17 天津和美生物技术有限公司 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用

Also Published As

Publication number Publication date
EP2479172B1 (en) 2013-10-09
PA8643901A1 (es) 2006-05-16
CA2579291C (en) 2011-11-29
EP1797068A1 (en) 2007-06-20
AU2005282728A1 (en) 2006-03-16
JP5701824B2 (ja) 2015-04-15
EP2479172A1 (en) 2012-07-25
CN101080400A (zh) 2007-11-28
US20060052609A1 (en) 2006-03-09
ES2437592T3 (es) 2014-01-13
JP2012207040A (ja) 2012-10-25
JP2008512379A (ja) 2008-04-24
BRPI0514865A (pt) 2008-06-24
HN2005000508A (es) 2010-10-08
TW200621748A (en) 2006-07-01
NZ554068A (en) 2009-07-31
ES2438725T3 (es) 2014-01-20
ZA200702382B (en) 2008-08-27
UY29097A1 (es) 2006-03-31
PE20060648A1 (es) 2006-07-14
MX2007002521A (es) 2007-05-09
US7863451B2 (en) 2011-01-04
EP1797068B1 (en) 2013-10-09
KR20070057907A (ko) 2007-06-07
WO2006028964A1 (en) 2006-03-16
AR050724A1 (es) 2006-11-15
CA2579291A1 (en) 2006-03-16
SV2007002219A (es) 2007-03-20
IL181674A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
GT200500103A (es) 4-fenilamino-quinazolin-6-il-amidas
GT200300296A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CU20120071A7 (es) DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
GT200600197A (es) Compuestos y composiciones como inhibidores de proteina quinasa
GT200600205A (es) Nuevos herbicidas
GT200600167A (es) Derivados de dihidrobenzofurano y usos de los mismos
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
PA8809001A1 (es) Compuestos organicos
CR7643A (es) Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6
GT200600342A (es) Compuestos de cicloalquilo amino-hidantoina y uso de estos para la modulacion de beta-secretasa
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
HN2002000067A (es) Inhibidores de la rho - quinasa.
GT200700039A (es) Derivados de triazolopirazina
UY30314A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PA8772701A1 (es) "COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO)-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA"
GT200600174A (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
CO6341625A2 (es) Derivados de indol como agentes anticáncer
GT200600024A (es) Derivados de triazol sustituidos como antagonistas de oxitocina
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
PA8667201A1 (es) Nuevos compuestos farmaceuticos
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
GT200600444A (es) Compuestos anti-hipercolesterolemicos
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6